argenx announces Extraordinary General Meeting of Shareholders on September 8, 2022
July 28 2022 - 2:30AM
July
28,
2022
Breda, the Netherlands – argenx
SE (Euronext & Nasdaq: ARGX), a global immunology company
committed to improving the lives of people suffering from severe
autoimmune diseases, today announced that an extraordinary general
meeting of shareholders will be held at 18:30 PM CEST on Thursday,
September 8, 2022 at the offices of Freshfields Bruckhaus Deringer
LLP, Strawinskylaan 10, 1077 XZ in Amsterdam, the Netherlands.The
shareholders and all other persons with meeting rights are invited
to attend the extraordinary general meeting of shareholders. The
formal notice of convocation (including information on attending
the meeting in person or by proxy, requirements for notification
and registration for the meeting and regarding the e-voting system)
is available on the argenx website www.argenx.com and on
www.abnamro.com/evoting.
AgendaThe sole agenda item will
be the proposed appointment of Mrs. Camilla Sylvest as
non-executive director of the Company.
The full agenda for the meeting as well as all
ancillary documents relevant for the meeting are available via the
argenx website and are also available for inspection at the argenx
offices. A free copy thereof may also be obtained by e-mailing
legal@argenx.com. argenx would like to encourage shareholders to
use the voting by (electronic) proxy option as referred to in the
convocation. The Company will provide a live audio-webcast of the
general meeting to enable as many shareholders as possible to
attend.
About argenx argenx is a
global immunology company committed to improving the lives of
people suffering from severe autoimmune diseases. Partnering with
leading academic researchers through its Immunology Innovation
Program (IIP), argenx aims to translate immunology breakthroughs
into a world-class portfolio of novel antibody-based medicines.
argenx developed and is commercializing the first-and-only approved
neonatal Fc receptor (FcRn) blocker in the U.S. and Japan. The
Company is evaluating efgartigimod in multiple serious autoimmune
diseases and advancing several earlier stage experimental medicines
within its therapeutic franchises. For more information, visit
www.argenx.com and follow us on LinkedIn, Twitter,
and Instagram
For further information, please
contact:
Media:Kelsey
Kirkkkirk@argenx.com
Investors:Beth
DelGiaccobdelgiacco@argenx.com
argenx (NASDAQ:ARGX)
Historical Stock Chart
From Jun 2024 to Jul 2024
argenx (NASDAQ:ARGX)
Historical Stock Chart
From Jul 2023 to Jul 2024